AR103832A1 - PHARMACEUTICAL FORMULATIONS OF AN INHIBITOR OF TYROSINE QUINASA BRUTON - Google Patents
PHARMACEUTICAL FORMULATIONS OF AN INHIBITOR OF TYROSINE QUINASA BRUTONInfo
- Publication number
- AR103832A1 AR103832A1 ARP160100550A ARP160100550A AR103832A1 AR 103832 A1 AR103832 A1 AR 103832A1 AR P160100550 A ARP160100550 A AR P160100550A AR P160100550 A ARP160100550 A AR P160100550A AR 103832 A1 AR103832 A1 AR 103832A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- pharmaceutical formulations
- conditions
- bruton
- quinasa
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 229940124291 BTK inhibitor Drugs 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 229940125814 BTK kinase inhibitor Drugs 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000007916 tablet composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000005550 wet granulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formulaciones farmacéuticas del inhibidor de tirosina quinasa de Bruton (Btk) 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona. Métodos para usar el inhibidor de Btk, solo o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluido el linfoma, y enfermedades o condiciones inflamatorias. Reivindicación 52: Un proceso para preparar la formulación de comprimido sólido de alta carga de cualquiera de las reivindicaciones 1 a 49, caracterizado porque el proceso comprende un método de granulación húmeda.Pharmaceutical formulations of the Bruton tyrosine kinase inhibitor (Btk) 1 - ((R) -3- (4-amino-3- (4-phenoxyphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one. Methods for using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. Claim 52: A process for preparing the high-load solid tablet formulation of any one of claims 1 to 49, characterized in that the process comprises a wet granulation method.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562127717P | 2015-03-03 | 2015-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103832A1 true AR103832A1 (en) | 2017-06-07 |
Family
ID=59254075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100550A AR103832A1 (en) | 2015-03-03 | 2016-03-02 | PHARMACEUTICAL FORMULATIONS OF AN INHIBITOR OF TYROSINE QUINASA BRUTON |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR103832A1 (en) |
| MA (1) | MA41643B1 (en) |
-
2016
- 2016-03-02 AR ARP160100550A patent/AR103832A1/en not_active Application Discontinuation
- 2016-03-02 MA MA41643A patent/MA41643B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA41643A (en) | 2018-01-09 |
| MA41643B1 (en) | 2024-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017011270A (en) | PHARMACEUTICAL COMPOSITIONS OF A BRUTON TYPEOSIN CINASE INHIBITOR. | |
| DOP2022000096A (en) | CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR | |
| MX2017001671A (en) | Novel formulations of a bruton's tyrosine kinase inhibitor. | |
| MX372673B (en) | A BTK INHIBITOR FOR USE IN THE TREATMENT OF PEMPHIGUUS AND SALTS AND SOLID FORMS THEREOF. | |
| MX2017012411A (en) | Co-crystals of a bruton's tyrosine kinase inhibitor. | |
| EA201591656A1 (en) | COMBINED THERAPY WITH IBRUTINIB | |
| EA201690746A1 (en) | TREATMENT WITH THE USE OF BLUTON AND IMMUNOTHERAPY THYROZINKINASE INHIBITORS | |
| MX2017015574A (en) | Inhibitors of bruton's tyrosine kinase. | |
| MX2017012430A (en) | Solvated forms of a bruton's tyrosine kinase inhibitor. | |
| NZ728392A (en) | High dosage strength tablets of rucaparib | |
| UY37559A (en) | PIRAZOLO [3,4-B] PIRIDINE AND PIRROLO [2,3-B] PIRIDINE AS INHIBITORS OF BRUTON TYPOSINE KINASE | |
| AR103832A1 (en) | PHARMACEUTICAL FORMULATIONS OF AN INHIBITOR OF TYROSINE QUINASA BRUTON | |
| MX2019000159A (en) | PIRROLO [2,3-D] PIRIDAZIN-4-SUBSTITUTED WAVES AND PIRAZOLO [3,4-D] PIRIDA ZIN-4-ONAS AS INHIBITORS OF PROTEIN KINASE. | |
| AR132685A2 (en) | PHARMACEUTICAL FORMULATIONS OF A BRUTON TYROSINE KINASE INHIBITOR | |
| AR098210A1 (en) | COMBINATIONS OF INHIBITORS OF THE TUTOSINA QUINASA DE BRUTON AND IMMUNOTHERAPIES | |
| TR201711933A2 (en) | HETEROCYCLIC COMPOUNDS THAT ARE SELECTIVE INHIBITING THE TYROZINE KINASE 2 (TYK2) ENZYME | |
| TH168817A (en) | Indolizine derivatives, which are phosphoenosides 3-kinase inhibitors. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |